From 2015 the Biopharmos Science-Research Center is a resident of Skolkovo Innovation Center, now the company works on the innovative project dedicated to the development of medication on the basis of short peptides with a non-narcotic type of analgesic effect.
Project results are addressed to patients who need relatively inexpensive, safe and effective products and who suffer from moderate and severe pain.
The main aim of the project is development of non-prescription medicinal products on the basis of created earlier short peptide sequences with non-narcotic type of analgesic effect (Patent RF № 2508295, PCT WO 2013141750 A1).
Using our method for determining the minimum sequence (domain) of full-length molecule maintaining its central activity, we have shown that for salmon calcitonin the amino acid sequence 16-21 (sCT16-21) possesses such activity (described as «active center» of calcitonin), as well as significant part of the full-length salmon calcitonin analgesic activity, effective in various modes of administration (suboccipital, intramuscular, intranasal and intrave-nous) on the various models of acute and tonic pain. From 288 variants of peptide sequences based on sCT16-21 eight were selected that have the highest stability and effectiveness of analgesic effect. These peptide sequences were protected by Patent RF № 2508295 and PCT WO 2013141750 A1 "Synthetic peptides with a non-narcotic type of analgesic effect", where the transition to the national patenting phases is done in the EU, US, Canada, Japan, India and Indonesia.
The challenge now is to develop the dosage form and conduct pre-clinical and clinical studies of the medication on the basis of developed earlier short peptides sequences with a non-narcotic type of analgesic effect.
The closest analogues by the type of non-narcotic analgesic effect are medicinal products based on salmon calcitonin, which possess prolonged anesthetic effect and now exist in different dosage forms: as spray or drops for nasal use, for oral and intramuscular administration, as well as suppositories. Sales of products on the basis of salmon calcitonin per year are about 300 mln USD. Products based on the full-length salmon calcitonin molecule are considered to be orphan, because they are not accessible to a wide range of customers, and are very expensive. The use of full-length salmon calcitonin molecule is associated with a certain risk of increased frequency of cancer. And although in March 2014 the FDA concluded that there is no conclusive evidence of a causal link between the use of calcitonin products and cancer, calcitonin use is still limited.
The unique advantage of the new product on the basis of short peptide sequences will be its safety and low cost (it is planned that the cost of the new medication will be less than of existing analogues in 10-15 times).